Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Triyaq-e-Nazla is a traditional Unani (Greco-Arabic) polyherbal formulation developed and manufactured by Dawakhana Tibbiya College, Aligarh Muslim University. It is formulated as a paste (Majoon) and is indicated for the treatment of common cold, catarrh (nasal and respiratory mucus), chronic cough, sneezing, and chronic sinusitis. The formulation acts as an expectorant and anti-inflammatory agent, soothing the irritated mucosa of the throat and upper respiratory tract, while also helping to increase resistance and endurance. Its key herbal constituents include *Acacia arabica*, *Cochlospermum religiosum*, *Commiphora myrrha*, *Coriandrum sativum*, *Glycyrrhiza glabra*, *Hyoscyamus niger*, *Lactuca scariola*, *Lavandula stoechas*, *Onosma bracteatum*, *Papaver somniferum*, *Rosa damascena*, and *Mentha piperita*.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Triyaq-e-Nazla.